Collaboration Management. Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]
Collaboration Management. 4.1 To implement, own and manage the Collaboration, Verdant and WindStrip will each designate team members responsible for engineering, design, development, and manufacture of Storage Systems to be integrated into the Integrated Systems.
4.2 The Collaboration will be managed and governed by such agreements (the “Operating Agreements”) customary for transactions of this type and consistent with this JDA as the parties may determine.
4.3 Verdant and WindStrip teams will be responsible for the cooperation between the parties and the joint development work on the Storage Systems (and, as applicable from time to time, the Integrated Systems) both during the development phase (the “Development Group”) and the operational phase (the “Working Group” and together with the Development Group, the “JDA Working Groups”) of the Integrated Systems.
4.4 The team members initially assigned to the Development Group and the initial leaders of each party’s team (“Management Leaders”) are set forth on Schedule 4.4. Either party may, by written notice to the other, update their list of team members or their Management Leaders of the Development Group with other representatives as may be reasonable. The team members initially assigned to the Working Group and the initial members of the management committee of the Collaboration (the “Management Committee”) will be set forth in the Operating Agreements. Either party may, by written notice to the other, update their list of team members of the Working Group or their Management Committee representatives with other representatives as may be reasonable pursuant to the terms and conditions of the Operating Agreements.
4.5 The JDA Working Groups will be responsible for the day-to-day development efforts and coordination in the development, implementation, operation and management of the Collaboration. Each JDA Working Group will convene—in person, or by telephone or video conference—no less frequently than weekly (except when a JDA Working Group deems it appropriate, the weekly sessions may be reset to be a minimum of bi-weekly), with the objective that the teams communicate routinely and regularly on all relevant aspects of the Storage Systems’ joint development and the Collaboration’s goals, including effective commercialization of the Integrated Systems.
4.5.1 The JDA Working Groups will establish, and modify or update as they deem appropriate, procedures and practices for their meetings and coordination.
4.5.2 The JDA Working Groups...
Collaboration Management. 4 2.1 Overview........................................................4 2.2 Joint Research Committee........................................4 2.3 Meetings of the Joint Research Committee........................4 2.4 Functions of the Joint Research Committee.......................5 2.5 Decision-Making of the Joint Research Committee.................5 2.6 Limitations on Joint Research Committee Powers..................5
Collaboration Management. A joint Steering Committee (Ciba-Chiron-Focal) will manage the research for the Embolization & Fragmentation Study, the First Generation Product Research, and the Radiopharmaceutical Product Research. The committee will periodically review the project plans and resource requirements and make revisions as necessary. Focal will define and manage it's internal resource to meet the goals described in this plan: A Steering committee composed of Ciba and Focal representative will manage the research for the Second Generation Product research with the first drug. The steering committee for the second drug program will be defined once the compound has been identified.
Collaboration Management. Each of the Parties shall appoint a single representative to act as that Party’s collaboration manager (each, a “Collaboration Manager”).
Collaboration Management. The Parties will manage the collaboration in good faith to (i) conduct the Transfer Plan as efficiently and effectively as possible in order for NBIX to submit an NDA for an Initial Product by the earliest date possible, for (ii) NBIX to develop the Initial Product for all indications in the Field for which it can be demonstrated there is a scientific and commercial justification (subject, in any event, to the provisions of Article 6) and (iii) to, subject to Section 7.2, support labelling designed to ensure the broadest commercial success for the Initial Product.
Collaboration Management. The purpose of the Collaboration management structure set forth below is to coordinate and expedite development and commercialization of Collaboration Products. The activities of the parties under this Agreement shall be managed in this structure only to the extent set forth herein. Each party shall assign individuals from within their respective organizations to each of the following positions. Each party may, in its sole discretion, may replace the assigned individuals at any time as necessary.
Collaboration Management. The purpose of the collaboration management structure set forth below is to coordinate and expedite the design, development, manufacture, * Material has been omitted pursuant to a request for confidential treatment, and such material has been filed separately with the SEC.
Collaboration Management. (a) The Research Program shall have a program director from each Party (each, a "Program Director, and together the "Program Directors"), initially [***] for Tranzyme and [***] for BMS), either Party may substitute their Program Director either on a temporary or permanent basis on written notice to the other Party. The Program Directors shall coordinate the research efforts of the Parties in conducting the Research Program.
(b) Each Party shall appoint a single individual to act as the single point of contact between the Parties to support the Research Program (the "Alliance Managers") other than the coordination of day-to-day research activities which will be coordinated by the Program Directors. As of the Effective Date, the Alliance Managers shall be [***] for BMS (the "BMS Alliance Manager") and [***] for Tranzyme (the "Tranzyme Alliance Manager"), either Party may substitute their Alliance Manager either on a temporary or permanent basis on written notice to the other Party. The Alliance Managers will:
(i) use good faith efforts to attend all meetings of the JSC, but shall be non-voting members at such meetings;
(ii) circulate the written minutes of the JSC meetings for review and approval by the Parties, and identify action items to be carried out by the Parties; and
(iii) be the first point of referral for all matters of conflict resolution, and bring disputes to the attention of the JSC in a timely manner.
Collaboration Management. 1.3.1 The collaboration will be managed by a planning committee of six members, including two members designated by each party, the General Manager, and the Vice General Manager of the collaboration. The planning committee will meet during year one (1) of the collaboration in order to ensure that Collaboration Services can be provided to meet the needs of customers. The planning committee will meet at such times as may be agreed by the parties, and may conduct meetings by telephone conference. The planning committee may review the status of projects, earning/cost information for individual project and financial plans. The planning committee may discuss, examine and evaluate how to prioritize spending to purchase or lease additional equipment and facilities as required by customer’s projects or GLP/CLIA regulations from any budget resulting from advanced payment from customers or profits from the collaboration’s contracts. The planning committee may also discuss quarterly-based or annual financial plan to enhance the collaboration’s GLP/CLIA capability and capacity.
